Search Filters:

The items contained in the list are being used to filter the search results. Click them to remove them from the search filter.
Displaying 341 - 360 of 783
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published Sort ascending
MHRA-101000-PIP01-23-M02 (update)
  • Rilzabrutinib
  • Treatment of immune thrombocytopenia.
  • Immunology -Rheumatology-Transplantation
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100678-PIP01-22-M01 (update)
  • vamikibart
  • Treatment of uveitic macular oedema
  • Ophthamology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101282-PIP01-23
  • eftilagimod alfa
  • Treatment of non-small cell lung cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101094-PIP01-23-M01 (update)
  • Givinostat
  • Treatment of Duchenne muscular dystrophy
  • Neurology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100312-PIP01-21-M02 (update)
  • RITLECITINIB TOSYLATE
  • Treatment of alopecia areata
  • Litfulo
  • Litfulo
  • Litfulo
  • Litfulo
  • Litfulo
  • Dermatology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100580-PIP01-22-M02 (update)
  • CEMIPLIMAB
  • Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)
  • Libtayo
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101375-PIP01-24-M01 (update)
  • FREMANEZUMAB
  • Prophylaxis of migraine headaches
  • Ajovy
  • Neurology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100690-PIP01-22-M02 (update)
  • IMIPENEM MONOHYDRATE
  • CILASTATIN SODIUM
  • RELEBACTAM MONOHYDRATE
  • Treatment of infections caused by gram-negative organisms.
  • RECARBRIO
  • RECARBRIO
  • RECARBRIO
  • RECARBRIO
  • RECARBRIO
  • RECARBRIO
  • RECARBRIO
  • RECARBRIO
  • RECARBRIO
  • RECARBRIO
  • RECARBRIO
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101409-PIP01-24-M01 (update)
  • IVOSIDENIB
  • Treatment of Acute Myeloid Leukaemia.
  • Tibsovo
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100038-PIP01-21-M03 (update)
  • Recombinant SARS-CoV-2 spike protein
  • Prevention of coronavirus disease 2019 (COVID-19)
  • VidPrevtyn Beta
  • VidPrevtyn Beta
  • Vaccines
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100931-PIP01-23-M02 (update)
  • mirikizumab
  • Treatment of ulcerative colitis
  • Treatment of Crohn's disease
  • Omvoh
  • Omvoh
  • Omvoh
  • Omvoh
  • Omvoh
  • Omvoh
  • Gastroenterology-Hepatology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100262-PIP01-21-M02 (update)
  • DALBAVANCIN HYDROCHLORIDE
  • Treatment of acute bacterial skin and skin structure infections (ABSSSI)
  • Xydalba
  • Xydalba
  • Xydalba
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100701-PIP01-22-M02 (update)
  • Recombinant Neisseria meningitis group B Protein 936-741
  • Meningococcal group W-135 oligosaccharides conjugated to Corynebacterium diptheriae CRM197 protein
  • Meningococcal group A oligosaccharides conjugated to Corynebacterium diptheriae CRM197 protein
  • Recombinant Neisseria meningitis group B Protein 287-953
  • Recombinant Neisseria meningitis group B Protein 961c
  • Meningococcal group Y oligosaccharides conjugated to Corynebacterium diptheriae CRM197 protein
  • Outer Membrane Vesicles (OMV) from N. meningitidis Strain NZ 98/254
  • Meningococcal group C oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein
  • Prevention of meningococcal meningitis
  • Not available at present
  • Vaccines
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100868-PIP01-23-M02 (update)
  • AFAMELANOTIDE
  • Treatment of erythropoietic protoporphyria (EPP)
  • SCENESSE
  • SCENESSE
  • SCENESSE
  • SCENESSE
  • SCENESSE
  • SCENESSE
  • Endocrinology-Gynaecology-Fertility-metabolism
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101362-PIP01-24-M01 (update)
  • ZANAMIVIR
  • Prevention of influenza
  • Treatment of influenza
  • Relenza (inhalation powder)
  • Dectova (solution for infusion)
  • Dectova
  • Dectova
  • Relenza
  • Relenza
  • Relenza
  • Relenza
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101360-PIP01-24-M01 (update)
  • Purified Rabies virus, WISTAR PM/WI 38-1503-3M strain (inactivated)
  • Prevention of rabies viral infection
  • Vaccines
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101359-PIP01-24
  • spesolimab
  • Treatment of Netherton syndrome
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Spevigo
  • Dermatology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-100273-PIP03-24
  • Derivative of 6-[2-(pyridin-2- yl)phenoxy]methyl}- 1,2,3,4-tetrahydroisoquinoline
  • Treatment of portal hypertension
  • Not available at present
  • Gastroenterology-Hepatology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101379-PIP01-24
  • Broadly neutralizing anti-HIV human monoclonal antibody (VH3810109)
  • Treatment of human immunodeficiency virus (HIV-1) infection
  • Not available at present
  • Infectious diseases
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101385-PIP01-24
  • Valemetostat tosilate
  • Treatment of mature T-cell neoplasms
  • EZHARMIA
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No